Complementary Healthcare Analysis - 2019-09-04
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.
| Top Gainers | |||||
| Company | Market Cap | Price | Change% | Volume | |
| Abeona Therapeutics Inc. (ABEO) | 171.43M | 2.94 | 90.91% | 23,159,736 | |
| Ardelyx, Inc. (ARDX) | 377.25M | 5.82 | 71.18% | 19,392,964 | |
| Cidara Therapeutics, Inc. (CDTX) | 66.58M | 2.35 | 39.88% | 17,029,812 | |
| The Medicines Company (MDCO) | 3.77B | 46.31 | 10.37% | 12,870,051 | |
| Canopy Growth Corporation (CGC) | 1.01B | 24.88 | 5.51% | 5,080,530 | |
| Top Losers | |||||
| Company | Market Cap | Price | Change% | Volume | |
| Clovis Oncology, Inc. (CLVS) | 290.65M | 5.18 | -7.66% | 2,908,817 | |
| CannTrust Holdings Inc. (CTST) | - | 1.64 | -5.75% | 2,080,198 | |
| ACADIA Pharmaceuticals Inc. (ACAD) | 3.75B | 25.26 | -8.68% | 1,751,444 | |
| Invitae Corporation (NVTA) | 2.15B | 22.67 | -6.55% | 1,433,725 | |
| Acorda Therapeutics, Inc. (ACOR) | 149.73M | 2.94 | -8.98% | 1,347,457 | |
| High volume stocks reaching new highs | |||||
| Company | Market Cap | Price | Change% | Volume | |
| Ardelyx, Inc. (ARDX) | 377.25M | 5.82 | 71.18% | 19,392,964 | |
| The Medicines Company (MDCO) | 3.77B | 46.31 | 10.37% | 12,870,051 | |
| Lannett Company, Inc. (LCI) | 356.31M | 10.23 | -0.68% | 7,956,158 | |
| Novo Nordisk A/S (NVO) | 99.50B | 52.90 | 1.52% | 1,211,093 | |
| Radius Health, Inc. (RDUS) | 1.32B | 28.55 | 0.88% | 806,895 | |
| High volume stocks reaching new lows | |||||
| Company | Market Cap | Price | Change% | Volume | |
| Mallinckrodt plc (MNK) | 254.69M | 2.55 | -1.54% | 12,430,278 | |
| Tilray, Inc. (TLRY) | 3.06B | 30.10 | 17.26% | 4,647,265 | |
| Rigel Pharmaceuticals, Inc. (RIGL) | 290.99M | 1.63 | -3.55% | 2,541,539 | |
| Sarepta Therapeutics, Inc. (SRPT) | 6.50B | 86.76 | -3.76% | 1,464,513 | |
| Adamis Pharmaceuticals Corporation (ADMP) | 51.08M | 0.84 | -10.54% | 1,043,057 | |
| Major Analyst Upgrades | |||||
| Company | Current Rating | New Rating | Analyst | Current Price | Target Price |
| Emergent Biosolutions (EBS) | Market Perform | Outperform | Wells Fargo & Co | $50.14 | |
| Intercept Pharmaceuticals (ICPT) | Neutral | Buy | Citigroup | $61.37 | $85.00 |
| Major Analyst Downgrades | |||||
| Company | Current Rating | New Rating | Analyst | Current Price | Target Price |
| n/a | |||||
| Major Insider Buys | |||||
| Company | Insider Name | Insider Title | Price | Qty | Value |
| Aileron Therapeutics Inc (ALRN) | Von Rickenbach Josef H | Dir | $0.77 | 3600 | +$2,771 |
| Amarillo Biosciences Inc (AMAR) | Chen Stephen T | Pres,COB,CEO,CFO, 10% | $0.40 | 1000 | +$400 |
| Apellis Pharmaceuticals, Inc. (APLS) | Sullivan Timothy Eugene | CFO | $29.71 | 11699 | +$347,630 |
| Cerecor Inc. (CERC) | Armistice Capital, LLC | Dir, 10% | $3.22 | 41764 | +$134,554 |
| Lannett Co Inc (LCI) | Crew Timothy C | CEO | $8.45 | 2000 | +$16,900 |
| Ligand Pharmaceuticals Inc (LGND) | Korenberg Matthew E | EVP,Finance, Strategy, CFO | $86.18 | 500 | +$43,091 |
| Nabriva Therapeutics Plc (NBRV) | Broom Colin Md | Dir | $2.03 | 10177 | +$20,668 |
| Veru Inc. (VERU) | Fisch Harry | Dir, 10% | $1.97 | 4000 | +$7,880 |
| Major Insider Sells | |||||
| Company | Insider Name | Insider Title | Price | Qty | Value |
| Collegium Pharmaceutical, Inc (COLL) | Hirsch David | Dir | $11.65 | -22106 | -$257,535 |
| Tyme Technologies, Inc. (TYME) | Demurjian Michael | 10% | $1.14 | -20000 | -$22,730 |
| Y-Mabs Therapeutics, Inc. (YMAB) | Wedell-Wedellsborg Johan | Dir, 10% | $26.58 | -89166 | -$2,370,074 |
Index Watch
NASDAQ Health CareINDEXNASDAQ: IXHC
iShares NASDAQ Biotechnology Index
NASDAQ: IBB
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.